Scarica l'app Stockscreener
1.61
4.17%
-0.07
Dopo l'orario di chiusura:
1.60
-0.01
-0.62%
Precedente Chiudi:
$1.68
Aprire:
$1.69
Volume 24 ore:
532.86K
Relative Volume:
1.25
Capitalizzazione di mercato:
$97.52M
Reddito:
-
Utile/perdita netta:
$-64.86M
Rapporto P/E:
-1.4375
EPS:
-1.12
Flusso di cassa netto:
$-55.66M
1 W Prestazione:
+8.78%
1M Prestazione:
+27.78%
6M Prestazione:
-2.42%
1 anno Prestazione:
-50.00%
Intervallo 1D:
$1.54
$1.69
Intervallo di 1 settimana:
$1.48
$1.73
Portata 52W:
$0.8551
$3.60
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
Nome
Acumen Pharmaceuticals Inc
Settore
Industria
Telefono
925-368-8508
Indirizzo
427 PARK ST., CHARLOTTESVILLE
Confronta ABOS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABOS
Acumen Pharmaceuticals Inc
|
1.61 | 101.16M | 0 | -64.86M | -55.66M | -1.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-17 | Iniziato | Citigroup | Buy |
| 2024-07-26 | Iniziato | Citigroup | Buy |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-07-20 | Ripresa | BofA Securities | Buy |
| 2023-05-18 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-07-15 | Iniziato | BTIG Research | Buy |
| 2022-06-30 | Iniziato | H.C. Wainwright | Buy |
| 2022-01-21 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-07-26 | Iniziato | BofA Securities | Neutral |
| 2021-07-26 | Iniziato | Credit Suisse | Outperform |
| 2021-07-26 | Iniziato | Stifel | Buy |
| 2021-07-26 | Iniziato | UBS | Buy |
Mostra tutto
Acumen Pharmaceuticals Inc Borsa (ABOS) Ultime notizie
Does Acumen Pharmaceuticals Inc. stock pay reliable dividendsSuperior capital gains - jammulinksnews.com
How high can Acumen Pharmaceuticals Inc. stock price go in 2025Exceptional growth trajectory - jammulinksnews.com
Is Acumen Pharmaceuticals Inc. stock overhyped or has real potentialPowerful market insights - jammulinksnews.com
Acumen Pharmaceuticals shares rise 2.92% after-hours following European Commission approval of DARZALEX Faspro® for multiple myeloma. - AInvest
Is RNST a good long term investmentRapid-fire capital growth - Autocar Professional
European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma - The Malaysian Reserve
Is Neo Concept International Group Holdings Limited a good long term investmentHigh-performance investment picks - Autocar Professional
What drives Comcast Corporation stock priceOutstanding risk-reward balance - jammulinksnews.com
What drives Acumen Pharmaceuticals Inc. stock priceSuperior capital gains - jammulinksnews.com
Nila Spaces Limited (542231) Signs Major DealExplosive market performance - jammulinksnews.com
Is ARTW a good long term investmentFree Investment Community - jammulinksnews.com
What analysts say about Nukkleus Inc. stockSuperior returns - jammulinksnews.com
What makes Acumen Pharmaceuticals Inc. stock price move sharplyFree Market Sentiment Analysis - Newser
Acumen Pharmaceuticals Inc. Stock Analysis and ForecastDynamic investment growth - jammulinksnews.com
What analysts say about Acumen Pharmaceuticals Inc. stockHigh-yield trading alerts - Autocar Professional
Is Acumen Pharmaceuticals Inc. a good long term investmentFree Investment Timing Strategies - Autocar Professional
West Pharmaceutical's Strategic Shift: How Robert McMahon's Financial Acumen Positions the Company for GLP-1 Dominance - AInvest
Central Nervous System (CNS) Biomarkers Market is expected - openPR.com
Is BKTI a good long term investmentRecord-breaking capital gains - jammulinksnews.com
Published on: 2025-07-20 14:18:28 - PrintWeekIndia
What analysts say about Rush Enterprises Inc. stockRapid wealth multiplication - jammulinksnews.com
What analysts say about BOLD stockMarket-crushing profits - jammulinksnews.com
Blue Chip Stocks Investor Friendly Stock ChoicesFree Capital Allocation Plans - Jammu Links News
Acumen and JCR enter collaboration to develop BBB-penetrating Alzheimer’s treatment - BioWorld MedTech
JCR Pharma links up with Acumen on Alzheimer’s research - The Pharma Letter
Acumen and JCR partner on brain delivery therapy for Alzheimer’s - Yahoo Finance
ai for factory safety and hazard detectionSafety First Trading Signals - Newser
Why Acumen Pharmaceuticals Inc. stock attracts strong analyst attentionSafer Investing With Bigger Upside - Newser
How CURRENC Group Inc. stock performs during market volatilitySafe and Scalable Investment Tips - Newser
Acumen Pharmaceuticals Inc (ABOS) Stock: A Comprehensive 52-Week Review - investchronicle.com
How Acumen Pharmaceuticals Inc. stock performs during market volatilityFree Exclusive Group - Newser
Why LINKBANCORP Inc. stock attracts strong analyst attentionPotential Rocket List - Newser
Why Veeco Instruments Inc. stock attracts strong analyst attentionFree Top Growth Stock Recommendations - Newser
How SELX stock performs during market volatilityVerified Return Tips - Newser
Acumen, JCR partner on brain barrier technology for Alzheimer’s treatment By Investing.com - Investing.com South Africa
Compass Therapeutics And 2 Other Promising Penny Stocks To Watch - Yahoo Finance
Acumen Pharmaceuticals, JCR to Develop Alzheimer's Disease Therapy - MarketScreener
Acumen, JCR partner on brain barrier technology for Alzheimer’s treatment - Investing.com Australia
ABOS SEC FilingsAcumen Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Acumen Pharmaceuticals Inc Azioni (ABOS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.32%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):